z-logo
Premium
Low prevalence of latent autoimmune diabetes in adults in northern India
Author(s) -
Sachan A.,
Zaidi G.,
Sahu R. P.,
Agrawal S.,
Colman P. G.,
Bhatia E.
Publication year - 2015
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.12644
Subject(s) - medicine , glutamate decarboxylase , diabetes mellitus , antibody , population , type 1 diabetes , type 2 diabetes , cohort , immunology , gastroenterology , endocrinology , environmental health , biology , biochemistry , enzyme
Aim To study the frequency of islet antibodies in a large cohort of clinic‐ and community‐based patients with Type 2 diabetes in northern India. Methods We measured glutamic acid decarboxylase ( GAD ) antibodies in 618 adults with Type 2 diabetes (378 patients with diabetes attending a hospital clinic, 240 patients diagnosed in a community survey) and in 192 healthy subjects residing in north India. Islet antigen 2 ( IA 2) antibodies were also studied in a proportion of the patients with diabetes ( n  =   492) and in a control population ( n  =   191). GAD and IA 2 antibodies were measured by immunoprecipitation of the respective 35 S‐labelled recombinant antigen. Results We found that GAD antibodies were present in nine (1.5%) patients with diabetes (clinic population: 0.8%, community study: 2.5%), a prevalence similar to that among the subjects without diabetes ( n  =   2; 1%). IA 2 antibodies were detected in seven patients with Type 2 diabetes (1.4%) and in two healthy control subjects (1.0%). The frequency of either GAD or IA 2 antibodies was similar in people with and without diabetes (3.2 vs 2.1%). No subject was found to have both antibodies. Insulin requirement was higher among antibody‐positive than among antibody‐negative patients ( GAD antibody: 33 vs 6.3%; P  =   0.001; GAD or IA 2 antibody: 23.1 vs 6.4%; P  =   0.02); however, other clinical features were similar in the two groups. Conclusions In the present north‐Indian population with Type 2 diabetes, the overall prevalence of GAD antibodies and the prevalence of either GAD or IA 2 antibodies were considerably lower than those reported in white European populations.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom